MDV3100
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer
Trial Timeline
Jan 24, 2012 → Feb 26, 2018
NCT ID
NCT01565928About MDV3100
MDV3100 is a phase 1 stage product being developed by Astellas Pharma for Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01565928. Target conditions include Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Prostate Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01606982 | Pre-clinical | Completed |
| NCT01911741 | Phase 1 | Completed |
| NCT01565928 | Phase 1 | Completed |
| NCT01901133 | Phase 1 | Completed |
| NCT01911715 | Phase 1 | Completed |
| NCT01284920 | Phase 1/2 | Completed |
| NCT00510718 | Phase 1 | Completed |
Competing Products
20 competing products in Prostate Cancer